<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04935424</url>
  </required_header>
  <id_info>
    <org_study_id>20STW2-4-010-V1A3</org_study_id>
    <nct_id>NCT04935424</nct_id>
  </id_info>
  <brief_title>Evaluation of Treatment for Leukoderma by Cellular Level Resolution Full-field Optical Coherence Tomography</brief_title>
  <official_title>Evaluation of Treatment for Leukoderma by Cellular Level Resolution Full-field Optical Coherence Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Apollo Medical Optics, Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OCT is an optical technology that emerged as a non-invasive skin imaging for the skin. In&#xD;
      this protocol, the investigators plan to study the optical imaging features of leukoderma. An&#xD;
      estimated 50 subjects will be included in this trial.&#xD;
&#xD;
      This is an observational, non-randomised, non-controlled, prospective cohort study to observe&#xD;
      the feasibility of in vivo OCT as a image tool in the diagnosis of leukoderma. Use of the&#xD;
      device will not affect the clinical management of the subjects.&#xD;
&#xD;
      Scientific Aim:&#xD;
&#xD;
      To evaluate the feasibility ApolloVue S100 image system as a tool in the differential&#xD;
      diagnosis of leukoderma..&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To describe characteristic features seen by Full-field Optical Coherence Tomography of leukoderma disorders.</measure>
    <time_frame>6 months</time_frame>
    <description>The study is a descriptive one. To researche the characteristic images of leukoderma. No formal statistical testing of correlations will be performed. All images will be evaluated as a group. First, the investigator will review the OCT images for each imaging site and will determine the presence/absence of leukoderma. Next, comparing with the leukoderma disorders images to highlight any features that may assist in the OCT evaluation.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Leukoderma</condition>
  <arm_group>
    <arm_group_label>Experimental：Leukoderma</arm_group_label>
    <description>Device: ApolloVue® S100 image system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ApolloVue® S100 Image System (Apollo Medical Optics)</intervention_name>
    <description>The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group. The ApolloVue S100 image system is a high resolution OCT imaging system that provide real-time visualization of human skin tissue microstructure. The system provides cellular level, two-dimensional, cross-sectional (B-scan) and en face (E-scan) that can assist clinical diagnosis.The system is also equipped with imaging guiding system that could assist in position scanning skin area.</description>
    <arm_group_label>Experimental：Leukoderma</arm_group_label>
    <other_name>510(K) Number: K201552 (class II)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subject with at least one leukoderma lesion&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≧ 20&#xD;
&#xD;
          2. Subject with at least one leukoderma lesion&#xD;
&#xD;
          3. Willing to participate in the trial with informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 20&#xD;
&#xD;
          2. Pregnant woman or woman wishing to be pregnant during the study, or during&#xD;
             breastfeeding period&#xD;
&#xD;
          3. The investigators consider inappropriate to participate in the trial.&#xD;
&#xD;
          4. Open wound lesion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chau Yee Ng, MD</last_name>
    <phone>+886-3-3281200</phone>
    <phone_ext>3556</phone_ext>
    <email>cyng87@cgmh.org.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan City</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chau Yee Ng, MD</last_name>
      <phone>+886-3-3281200</phone>
      <phone_ext>3556</phone_ext>
      <email>cyng87@cgmh.org.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Liu Z, Jiang M, Zhao J, Wang Q, Zhang C, Gao M, Gu M, Xiang L. Efficacy of a wound-dressing biomaterial on prevention of postinflammatory hyperpigmentation after suction blister epidermal grafting in stable vitiligo patients: a controlled assessor-blinded clinical study with in vitro bioactivity investigation. Arch Dermatol Res. 2020 Nov;312(9):635-645. doi: 10.1007/s00403-020-02049-2. Epub 2020 Feb 27.</citation>
    <PMID>32107629</PMID>
  </reference>
  <reference>
    <citation>Abdel-Malek ZA, Jordan C, Ho T, Upadhyay PR, Fleischer A, Hamzavi I. The enigma and challenges of vitiligo pathophysiology and treatment. Pigment Cell Melanoma Res. 2020 Nov;33(6):778-787. doi: 10.1111/pcmr.12878. Epub 2020 Apr 12. Review.</citation>
    <PMID>32198977</PMID>
  </reference>
  <reference>
    <citation>Li W, Wang S, Xu AE. Role of in vivo reflectance confocal microscopy in determining stability in vitiligo: a preliminary study. Indian J Dermatol. 2013 Nov;58(6):429-32. doi: 10.4103/0019-5154.119948.</citation>
    <PMID>24249892</PMID>
  </reference>
  <reference>
    <citation>Alghamdi KM, Kumar A, Taïeb A, Ezzedine K. Assessment methods for the evaluation of vitiligo. J Eur Acad Dermatol Venereol. 2012 Dec;26(12):1463-71. doi: 10.1111/j.1468-3083.2012.04505.x. Epub 2012 Mar 15. Review.</citation>
    <PMID>22416879</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>August 8, 2021</last_update_submitted>
  <last_update_submitted_qc>August 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Chau Yee Ng</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Optical coherence tomography (OCT)</keyword>
  <keyword>dermatology</keyword>
  <keyword>Full-Field OCT</keyword>
  <keyword>Non-invasive image system</keyword>
  <keyword>Leukoderma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypopigmentation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

